Human medicines European public assessment report (EPAR): Suboxone, buprenorphine,naloxone, Date of authorisation: 26/09/2006, Revision: 24, Status: Withdrawn

Human medicines European public assessment report (EPAR): Tolvaptan Accord, tolvaptan, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 36, Status: Authorised

Data in regulation: Big data and other sources

Human medicines European public assessment report (EPAR): Joenja, leniolisib, Date of authorisation: 21/05/2026, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Skytrofa (previously Lonapegsomatropin Ascendis Pharma), lonapegsomatropin, Date of authorisation: 11/01/2022, Revision: 7, Status: Authorised

ACT EU workshop on multiplicity in confirmatory clinical trials: From two-arm to platform trials , Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 27 November 2026, 09:00 (CET) to 27 November 2026, 15:00 (CET)

Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (21 August 2026 - 17 September 2026)

Suboxone : EPAR - Procedural steps taken before authorisation